carotuximab — Topline data
Q3 2026
Continued execution of our Phase 1 clinical trial of ENV-105 in non-small cell lung cancer, with the goal of announcing key safety and efficacy results by Q3 2026Source filing
KAPA biotech catalysts & pipeline
KAIROS PHARMA LTD · Data as of 2026-09-08